---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-190531"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2022-07-08T23:59:59+00:00"
generated_at: "2026-06-24T18:17:29.820559+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aileron Therapeutics CMO Vojislav Vukovic departs; severance agreement reached

## Summary
- Chief Medical Officer Vojislav Vukovic, M.D., Ph.D. separated from Aileron on July 8, 2022.
- Separation was not due to any disagreement with the company regarding operations, policies, or practices.
- Severance includes nine months of semi-monthly salary continuation and COBRA premium payments.
- Separation agreement contains customary release of claims, non-solicit, non-disparagement, and cooperation covenants.
- No successor or interim CMO has been announced as of the filing date.

## SEC filing metadata
- accession: 0001193125-22-190531
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2022-07-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312522190531/0001193125-22-190531-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312522190531/d367608d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-190531
- JSON: https://secwatch.observer/filing/0001193125-22-190531.json
- Plain text: https://secwatch.observer/filing/0001193125-22-190531.txt

## Key facts
- Executive change
  Vojislav Vukovic departed as Chief Medical Officer at Rein Therapeutics, Inc..
  - Action: separated
  - Role: Chief Medical Officer
  source text: On July 8, 2022, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), entered into a Separation and Release of Claims Agreement with Vojislav Vukovic, M.D., Ph.D. (the “Separation Agreement”), which provides for Dr. Vukovic’s separation of employment as Senior Vice President, Chief Medical Officer of the Company, effective July 8, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1420565/000119312522190531/0001193125-22-190531-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.